Understanding ABIN1 in Lupus Kidney Disease
ABIN1 dysfunction in Lupus Nephritis
This project looks at how a protein called ABIN1 contributes to lupus kidney disease, especially in African American patients, to find better ways to help them.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Louisville NIH-funded |
| Lab location | 1 site (Louisville, United States) |
| Project ID | NIH-11125954 on NIH RePORTER |
What this research studies
Lupus kidney disease is a serious complication of lupus that often leads to kidney failure, particularly in African American patients, and current treatments can be harsh and not always effective. This project explores how changes in a specific protein, ABIN1, which is linked to a gene called TNIP1, might make lupus kidney disease worse. Researchers want to understand the exact ways ABIN1 affects immune cells and whether these genetic differences explain why the disease is more severe in African Americans. The goal is to uncover new biological pathways that could lead to more targeted and effective treatments.
Who could benefit from this research
Good fit: Patients with lupus kidney disease, particularly those of African American descent, who are interested in understanding the genetic factors influencing their condition, could potentially benefit from future treatments developed from this research.
Not a fit: Patients without lupus or lupus kidney disease, or those not interested in research focused on genetic and molecular mechanisms, would not directly benefit from this specific investigation.
Why it matters
Potential benefit: If successful, this work could lead to new treatments for lupus kidney disease, especially for African American patients, by targeting the specific genetic and molecular pathways involved.
How similar studies have performed: Previous studies have linked TNIP1 gene variants to lupus and lupus kidney disease, and preliminary data from this team suggest these variants are associated with disease severity in African Americans.
Where this research is happening
Louisville, United States
- University of Louisville — Louisville, United States (Active)
Researchers
- Principal investigator: Powell, David W. — University of Louisville
- Study coordinator: Powell, David W.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.